| Zacks Company Profile for Suvanza Inc. (SUVZ : OTC) |
|
|
| |
| • Company Description |
| Suvanza, Inc. provides topical treatment with Mycophin anti-Fungal Gel. The Company has successfully completed clinical trials, for such indications as Onychomycosis, Tinea Capitis and Tinea Corporis. Suvanza's delivery system uses less active ingredients, has reduced systemic uptake, and provides the opportunity to use multiple actives, which do not interact prior to application. The Company's Technology consists of three components: Active Ingredient, Macro Bead Technology and Protecting Gel Vehicle. The Active Ingredient uses physical chemical modulation in nano vesicle formulation, for a targeted penetration in skin, hair and nails diseases. The Suvanza Technology targets disease sites such as skin surface, hair and nails, filling a void in topical therapy in those areas.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $ |
Daily Weekly Monthly
 |
| 20 Day Moving Average: shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: |
| 52 Week High: $0.00 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
% |
% |
| 12 Week |
% |
% |
| Year To Date |
% |
% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
7175 NW EVERGREEN PARKWAY
-
HILLSBORO,OR 97124
USA |
ph: 503-615-3200
fax: 916-643-2280 |
None |
None |
|
|
| |
| • General Corporate Information |
Officers
Frank G. Hausmann, Jr. - President; C.E.O. ; Chairman of the Board & Acting
David Billstrom - Director
Merrill A. McPeak - Director
G. Gerald Pratt - Director
Frederick M. Stevens - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: INTERNET SOFTWARE
Sector: Computer and Technology
CUSIP: 869551101
SIC: 7372
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 3.00 (0.01:1)
Beta:
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: % |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
